{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:24:02Z","timestamp":1787185442488,"version":"build-2736575974"},"reference-count":46,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Despite multiple treatment options available for obsessive-compulsive disorder (OCD), the response still remains unsatisfactory due to various factors. Hence, there is a continuous need to explore newer treatment modalities for OCD. Neuroinflammation might be one such contributing factor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>We aimed to study the clinical outcome of early Celecoxib (Selective Cyclooxygenase-2 Inhibitor) add-on therapy to fluoxetine treatment in OCD over 8\u2009weeks and explored the association of the outcomes with biochemical parameters, serum interleukin-6 (IL-6) and brain-derived neurotrophic factor (BDNF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Forty-four drug-naive patients diagnosed with OCD (as per International Classification of Diseases-10) were recruited and randomized into 2 groups of 22 participants each. The study participants received fluoxetine and celecoxib (800\u2009mg\/day), and the control group received fluoxetine and a placebo. The clinical variables were measured at 0, 2, 4 and 8\u2009weeks using the standard Yale-Brown Obsessive Compulsive Scale (YBOCS) for severity of symptoms. Serum IL-6 and BDNF were assessed at 0 and 8\u2009weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The study group showed a greater mean change (6.56\u2009\u00b1\u20091.04) of YBOCS scores over 8\u2009weeks (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009\u2a7d\u20090.001, Hedge\u2019s\n                      <jats:italic toggle=\"yes\">g<\/jats:italic>\n                      \u2009=\u20091.918). Response rate was higher in the study group (33%) than in controls (11.1%; Number Needed to Treat\u2009=\u20094.2). Reduction in YBOCS scores was positively correlated with the decrease in inflammatory marker (IL-6) in the study group (\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      \u2009=\u20090.478,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.033). No significant side effects were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Celecoxib holds promise as a potentially safe early add-on treatment in OCD for rapid improvement in psychopathology, with further research warranted in this area.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration:<\/jats:title>\n                    <jats:p>\n                      The study was registered with the Clinical Trial Registry of India (Reference no. CTRI\/2022\/01\/039407).\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/ctri.nic.in\/Clinicaltrials\/rmaindet.php?trialid=64361&amp;EncHid=59518.51563&amp;modid=1&amp;compid=19\">https:\/\/ctri.nic.in\/Clinicaltrials\/rmaindet.php?trialid=64361&amp;EncHid=59518.51563&amp;modid=1&amp;compid=19<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811251389556","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T05:30:17Z","timestamp":1764307817000},"page":"1437-1445","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring early add-on celecoxib treatment in OCD: Results from a preliminary randomized, double-blind, placebo-controlled trial"],"prefix":"10.1177","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3420-8275","authenticated-orcid":false,"given":"Shivangini","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Psychiatry, King George\u2019s Medical University, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Nischal","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, King George\u2019s Medical University, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Nischal","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, King George\u2019s Medical University, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyendra Kumar","family":"Singh","sequence":"additional","affiliation":[{"name":"Stem Cell\/Cell Culture Lab, Centre for Advance Research, King George\u2019s Medical University, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Government Medical College, Kannauj, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adarsh","family":"Tripathi","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, King George\u2019s Medical University, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.2174\/1871527317666181105162347"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocrd.2020.100581"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1998.8966"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111437"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0306-5251.2002.01770.x"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000356"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01700-4"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199500291-00004"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.comppsych.2011.12.007"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2020.08.008"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/FBP.0000000000000468"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12103497"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e32834f94cb"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1989.01810110048007"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1086\/377003"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2011.132"},{"key":"e_1_3_2_18_1","volume-title":"IBM SPSS Statistics for Windows","author":"IBM Corp","year":"2017","unstructured":"IBM Corp (2017) IBM SPSS Statistics for Windows (Version 25.0) [Computer program]. Armonk, NY: IBM Corp."},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5545.196976"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.3352\/jeehp.2021.18.17"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.comppsych.2018.11.013"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1559667"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S211703"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1155\/2007\/65704"},{"key":"e_1_3_2_25_1","first-page":"5","article-title":"Practice guideline for the treatment of patients with obsessive-compulsive disorder","volume":"164","author":"Koran LM","year":"2007","unstructured":"Koran LM, Hanna GL, Hollander E, et al. (2007) Practice guideline for the treatment of patients with obsessive-compulsive disorder. The American Journal of Psychiatry 164(7 Suppl): 5\u201353.","journal-title":"The American Journal of Psychiatry"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-45106-5_9"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.IDT.0000371058.38341.b3"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2019.00363"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2015.00134"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2015.08.011"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2017.10.014"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26654"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5545.58308"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2011.01.019"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1997.00601.x"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.32598\/bcn.2021.1998.1"},{"issue":"4","key":"e_1_3_2_37_1","first-page":"136","article-title":"Celecoxib as an adjuvant to fluvoxamine in moderate to severe obsessive-compulsive disorder: A double-blind, placebo-controlled, randomized trial","volume":"48","author":"Shalbafan M","year":"2015","unstructured":"Shalbafan M, Mohammadinejad P, Shariat S-V, et al. (2015) Celecoxib as an adjuvant to fluvoxamine in moderate to severe obsessive-compulsive disorder: A double-blind, placebo-controlled, randomized trial. Pharmacopsychiatry 48(4\u20135): 136\u2013140.","journal-title":"Pharmacopsychiatry"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.15562\/bmj.v8i2.1460"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S385117"},{"key":"e_1_3_2_40_1","unstructured":"The Global Burden of Disease: 2004 Update (2008) WHO. Available at: https:\/\/www.who.int\/publications-detail-redirect\/9789241563710 (accessed 3 July 2022)."},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocrd.2021.100635"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2011.04.002"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v10.i22.7872"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2022.110743"},{"key":"e_1_3_2_45_1","volume-title":"The ICD-10 classification of mental and behavioural disorders: Diagnostic criteria for research","author":"World Health Organization","year":"1993","unstructured":"World Health Organization (1993) The ICD-10 classification of mental and behavioural disorders: Diagnostic criteria for research. Geneva: World Health Organization."},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12031-017-0922-0"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.2212_1.x"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251389556","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811251389556","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251389556","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:28:42Z","timestamp":1787182122000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811251389556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1177\/02698811251389556"],"URL":"https:\/\/doi.org\/10.1177\/02698811251389556","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]}}}